Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study Changing Generic Clozapine Formulation to FazaClo® (Clozapine, USP) Orally Disintegrating Tablets in Stable Patients With Schizophrenia or Schizoaffective Disorder

NCT00501618 is registered in ClinicalTrials.gov with Manhattan Psychiatric Center as lead sponsor.

NCT NCT00501618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00501618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study Changing Generic Clozapine Formulation to FazaClo® (Clozapine, USP) Orally Disintegrating Tablets in Stable Patients With Schizophrenia or Schizoaffective Disorder
Lead sponsor
Manhattan Psychiatric Center
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2006
Completion date
July 31, 2009
Enrollment
20 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia